IBI110

News alerts, weekly reports and conference planners

Company:

Innovent Biologics

Drug class:

LAG-3 inhibitor

Related drugs:

HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	sintilimab + IBI110 Sensitive: C3 – Early Trials sintilimab + IBI110 Sensitive : C3	sintilimab + IBI110 Sensitive: C3 – Early Trials sintilimab + IBI110 Sensitive : C3
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	sintilimab + IBI110 Sensitive: C3 – Early Trials sintilimab + IBI110 Sensitive : C3	sintilimab + IBI110 Sensitive: C3 – Early Trials sintilimab + IBI110 Sensitive : C3

Associations
(2)